Investor Relations

Better Therapeutics is a prescription digital therapeutics (PDT) company developing a novel form of cognitive behavioral therapy to address the root causes of cardiometabolic diseases. The company has developed a proprietary platform for the development of FDA-regulated, software-based solutions for type 2 diabetes, heart disease and other conditions. The cognitive behavioral therapy delivered by Better Therapeutics’ PDTs is designed to enable changes in neural pathways of the brain so lasting changes in behavior become possible. This approach has the potential to dramatically improve patient health while lowering healthcare costs.

Corporate Profile

Better Therapeutics was founded upon the realization that nearly half a trillion dollars are spent each year treating the symptoms or effects of cardiometabolic diseases while little is being done to address the behaviors that cause them. Better has created prescription software that it believes has the opportunity to fundamentally change the treatment of a broad range of cardiometabolic diseases.

The company is focused on creating significant patient impact through the launch of its first product for treating type 2 diabetes in 2023, and anticipates launching additional products treating other cardiometabolic conditions by addressing root causes of disease. Better Therapeutics’ prescription digital therapeutics are intended to be prescribed by physicians and reimbursed like traditional medicines.

lnk Profile

Learn More

Stock Information

Data Provided by Refinitiv. Minimum 15 minutes delayed.

Recent Press Releases
Mar 04, 2024
Company to host sponsored education session on Saturday, March 09, 2024 ; Expanding access to a high quality and effective lifestyle modification intervention SAN FRANCISCO --(BUSINESS WIRE)--Mar. 4, 2024-- Better Therapeutics, Inc. (NASDAQ: BTTX), a pioneer in developing prescription digital

lnk Releases